NEW YORK, Nov. 25, 2020 /PRNewswire/ --Amid the COVID-19 crisis, the global market for Cell Harvesting estimated at US$233.2 Million in the year 2020, is projected to reach a revised size of US$381.4 Million by 2027, growing at a CAGR of 7.3% over the period 2020-2027.Manual, one of the segments analyzed in the report, is projected to grow at a 7.9% CAGR to reach US$284.4 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Automated segment is readjusted to a revised 5.6% CAGR for the next 7-year period. This segment currently accounts for a 28.3% share of the global Cell Harvesting market.
Read the full report: https://www.reportlinker.com/p05798117/?utm_source=PRN
The U.S. Accounts for Over 30.9% of Global Market Size in 2020, While China is Forecast to Grow at a 10.4% CAGR for the Period of 2020-2027
The Cell Harvesting market in the U.S. is estimated at US$72 Million in the year 2020. The country currently accounts for a 30.86% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$34.9 Million in the year 2027 trailing a CAGR of 10.4% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.1% and 7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.6% CAGR while Rest of European market (as defined in the study) will reach US$34.9 Million by the year 2027.We bring years of research experience to this 5th edition of our report. The 226-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others,
Read the full report: https://www.reportlinker.com/p05798117/?utm_source=PRN
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1
II. EXECUTIVE SUMMARY II-1
1. MARKET OVERVIEW II-1Cell Harvesting - A Prelude II-1Impact of Covid-19 and a Looming Global Recession II-1With Stem Cells Holding Potential to Emerge as Savior forHealthcare System Struggling with COVID-19 Crisis, Demand forCell Harvesting to Grow II-1Select Clinical Trials in Progress for MSCs in the Treatment ofCOVID-19 II-2Lack of Antiviral Therapy Brings Spotlight on MSCs as PotentialOption to Treat Severe Cases of COVID-19 II-3Stem Cells Garner Significant Attention amid COVID-19 Crisis II-3Growing R&D Investments & Rising Incidence of Chronic Diseasesto Drive the Global Cell Harvesting Market over the Long-term II-3US Dominates the Global Market, Asia-Pacific to ExperienceLucrative Growth Rate II-4Biopharmaceutical & Biotechnology Firms to Remain Key End-User II-4Remarkable Progress in Stem Cell Research Unleashes UnlimitedAvenues for Regenerative Medicine and Drug Development II-4Drug Development II-5Therapeutic Potential II-5
2. FOCUS ON SELECT PLAYERS II-6Recent Market Activity II-7Innovations and Advancements II-7
3. MARKET TRENDS & DRIVERS II-8Development of Regenerative Medicine Accelerates Demand forCell Harvesting II-8The Use of Mesenchymal Stem Cells in Regenerative Medicine toDrive the Cell Harvesting Market II-8Rise in Volume of Orthopedic Procedures Boosts Prospects forStem Cell, Driving the Cell Harvesting II-9Exhibit 1: Global Orthopedic Surgical Procedure Volume (2010-2020) (in Million) II-11Increasing Demand for Stem Cell Based Bone Grafts: PromisingGrowth Ahead for Cell Harvesting II-11Spectacular Advances in Stem Cell R&D Open New Horizons forRegenerative Medicine II-12Exhibit 2: Global Regenerative Medicines Market by Category(2019): Percentage Breakdown for Biomaterials, Stem CellTherapies and Tissue Engineering II-13Stem Cell Transplants Drive the Demand for Cell Harvesting II-13Rise in Number of Hematopoietic Stem Cell TransplantationProcedures Propels Market Expansion II-15Growing Incidence of Chronic Diseases to Boost the Demand forCell Harvesting II-16Exhibit 3: Global Cancer Incidence: Number of New Cancer Casesin Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 II-17Exhibit 4: Global Number of New Cancer Cases and Cancer-relatedDeaths by Cancer Site for 2018 II-18Exhibit 5: Number of New Cancer Cases and Deaths (in Million)by Region for 2018 II-19Exhibit 6: Fatalities by Heart Conditions: Estimated PercentageBreakdown for Cardiovascular Disease, Ischemic Heart Disease,Stroke, and Others II-19Exhibit 7: Rising Diabetes Prevalence Presents Opportunity forCell Harvesting: Number of Adults (20-79) with Diabetes (inMillions) by Region for 2017 and 2045 II-20Ageing Demographics to Drive Demand for Stem Cell Banking II-20Global Aging Population Statistics - Opportunity Indicators II-21Exhibit 8: Expanding Elderly Population Worldwide: Breakdown ofNumber of People Aged 65+ Years in Million by GeographicRegion for the Years 2019 and 2030 II-21Exhibit 9: Life Expectancy for Select Countries in Number ofYears: 2019 II-22High Cell Density as Major Bottleneck Leads to Innovative CellHarvesting Methods II-22Advanced Harvesting Systems to Overcome Centrifugation Issues II-23Sophisticated Filters for Filtration Challenges II-23Innovations in Closed Systems Boost Efficiency & Productivityof Cell Harvesting II-23Enhanced Harvesting and Separation of Micro-Carrier Beads II-24
4. GLOBAL MARKET PERSPECTIVE II-25Table 1: World Current & Future Analysis for Cell Harvesting byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2020 through 2027 II-25
Table 2: World Historic Review for Cell Harvesting byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2012 through 2019 II-26
Table 3: World 15-Year Perspective for Cell Harvesting byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld Markets for Years 2012, 2020 & 2027 II-27
Table 4: World Current & Future Analysis for Manual byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2020 through 2027 II-28
Table 5: World Historic Review for Manual by Geographic Region- USA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2012 through 2019 II-29
Table 6: World 15-Year Perspective for Manual by GeographicRegion - Percentage Breakdown of Value Sales for USA, Canada,Japan, China, Europe, Asia-Pacific and Rest of World for Years2012, 2020 & 2027 II-30
Table 7: World Current & Future Analysis for Automated byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2020 through 2027 II-31
Table 8: World Historic Review for Automated by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific andRest of World Markets - Independent Analysis of Annual Sales inUS$ Thousand for Years 2012 through 2019 II-32
Table 9: World 15-Year Perspective for Automated by GeographicRegion - Percentage Breakdown of Value Sales for USA, Canada,Japan, China, Europe, Asia-Pacific and Rest of World for Years2012, 2020 & 2027 II-33
Table 10: World Current & Future Analysis for Peripheral Bloodby Geographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2020 through 2027 II-34
Table 11: World Historic Review for Peripheral Blood byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2012 through 2019 II-35
Table 12: World 15-Year Perspective for Peripheral Blood byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2012, 2020 & 2027 II-36
Table 13: World Current & Future Analysis for Bone Marrow byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2020 through 2027 II-37
Table 14: World Historic Review for Bone Marrow by GeographicRegion - USA, Canada, Japan, China, Europe, Asia-Pacific andRest of World Markets - Independent Analysis of Annual Sales inUS$ Thousand for Years 2012 through 2019 II-38
Table 15: World 15-Year Perspective for Bone Marrow byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2012, 2020 & 2027 II-39
Table 16: World Current & Future Analysis for Umbilical Cord byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2020 through 2027 II-40
Table 17: World Historic Review for Umbilical Cord byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2012 through 2019 II-41
Table 18: World 15-Year Perspective for Umbilical Cord byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2012, 2020 & 2027 II-42
Table 19: World Current & Future Analysis for Adipose Tissue byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2020 through 2027 II-43
Table 20: World Historic Review for Adipose Tissue byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2012 through 2019 II-44
Table 21: World 15-Year Perspective for Adipose Tissue byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2012, 2020 & 2027 II-45
Table 22: World Current & Future Analysis for OtherApplications by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific and Rest of World Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2020 through2027 II-46
Table 23: World Historic Review for Other Applications byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2012 through 2019 II-47
Table 24: World 15-Year Perspective for Other Applications byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2012, 2020 & 2027 II-48
Table 25: World Current & Future Analysis for Biotech &Biopharma Companies by Geographic Region - USA, Canada, Japan,China, Europe, Asia-Pacific and Rest of World Markets -Independent Analysis of Annual Sales in US$ Thousand for Years2020 through 2027 II-49
Table 26: World Historic Review for Biotech & BiopharmaCompanies by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific and Rest of World Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 II-50
Table 27: World 15-Year Perspective for Biotech & BiopharmaCompanies by Geographic Region - Percentage Breakdown of ValueSales for USA, Canada, Japan, China, Europe, Asia-Pacific andRest of World for Years 2012, 2020 & 2027 II-51
Table 28: World Current & Future Analysis for ResearchInstitutes by Geographic Region - USA, Canada, Japan, China,Europe, Asia-Pacific and Rest of World Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2020 through2027 II-52
Table 29: World Historic Review for Research Institutes byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2012 through 2019 II-53
Table 30: World 15-Year Perspective for Research Institutes byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2012, 2020 & 2027 II-54
Table 31: World Current & Future Analysis for Other End-Uses byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2020 through 2027 II-55
Table 32: World Historic Review for Other End-Uses byGeographic Region - USA, Canada, Japan, China, Europe,Asia-Pacific and Rest of World Markets - Independent Analysisof Annual Sales in US$ Thousand for Years 2012 through 2019 II-56
Table 33: World 15-Year Perspective for Other End-Uses byGeographic Region - Percentage Breakdown of Value Sales forUSA, Canada, Japan, China, Europe, Asia-Pacific and Rest ofWorld for Years 2012, 2020 & 2027 II-57
III. MARKET ANALYSIS III-1
GEOGRAPHIC MARKET ANALYSIS III-1
UNITED STATES III-1Increasing Research on Stem Cells for Treating COVID-19 todrive the Cell Harvesting Market III-1Rising Investments in Stem Cell-based Research Favors CellHarvesting Market III-1Exhibit 10: Stem Cell Research Funding in the US (in US$Million) for the Years 2011 through 2017 III-2A Strong Regenerative Medicine Market Drives Cell HarvestingDemand III-2Arthritis III-3Exhibit 11: Percentage of Population Diagnosed with Arthritisby Age Group III-3Rapidly Ageing Population: A Major Driving Demand for CellHarvesting Market III-4Exhibit 12: North American Elderly Population by Age Group(1975-2050) III-4Increasing Incidence of Chronic Diseases Drives Focus onto CellHarvesting III-5Exhibit 13: CVD in the US: Cardiovascular Disease* Prevalencein Adults by Gender & Age Group III-5Rising Cancer Cases Spur Growth in Cell Harvesting Market III-5Exhibit 14: Estimated Number of New Cancer Cases and Deaths inthe US (2019) III-6Exhibit 15: Estimated New Cases of Blood Cancers in the US(2020) - Lymphoma, Leukemia, Myeloma III-7Exhibit 16: Estimated New Cases of Leukemia in the US: 2020 III-7Market Analytics III-8Table 34: USA Current & Future Analysis for Cell Harvesting byType - Manual and Automated - Independent Analysis of AnnualSales in US$ Thousand for the Years 2020 through 2027 III-8
Table 35: USA Historic Review for Cell Harvesting by Type -Manual and Automated Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2012 through 2019 III-9
Table 36: USA 15-Year Perspective for Cell Harvesting by Type -Percentage Breakdown of Value Sales for Manual and Automatedfor the Years 2012, 2020 & 2027 III-10
Table 37: USA Current & Future Analysis for Cell Harvesting byApplication - Peripheral Blood, Bone Marrow, Umbilical Cord,Adipose Tissue and Other Applications - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027 III-11
Table 38: USA Historic Review for Cell Harvesting byApplication - Peripheral Blood, Bone Marrow, Umbilical Cord,Adipose Tissue and Other Applications Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 III-12
Table 39: USA 15-Year Perspective for Cell Harvesting byApplication - Percentage Breakdown of Value Sales forPeripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissueand Other Applications for the Years 2012, 2020 & 2027 III-13
Table 40: USA Current & Future Analysis for Cell Harvesting byEnd-Use - Biotech & Biopharma Companies, Research Institutesand Other End-Uses - Independent Analysis of Annual Sales inUS$ Thousand for the Years 2020 through 2027 III-14
Table 41: USA Historic Review for Cell Harvesting by End-Use -Biotech & Biopharma Companies, Research Institutes and OtherEnd-Uses Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2012 through 2019 III-15
Table 42: USA 15-Year Perspective for Cell Harvesting byEnd-Use - Percentage Breakdown of Value Sales for Biotech &Biopharma Companies, Research Institutes and Other End-Uses forthe Years 2012, 2020 & 2027 III-16
CANADA III-17Market Overview III-17Exhibit 17: Number of New Cancer Cases in Canada: 2019 III-17Market Analytics III-18Table 43: Canada Current & Future Analysis for Cell Harvestingby Type - Manual and Automated - Independent Analysis of AnnualSales in US$ Thousand for the Years 2020 through 2027 III-18
Table 44: Canada Historic Review for Cell Harvesting by Type -Manual and Automated Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2012 through 2019 III-19
Table 45: Canada 15-Year Perspective for Cell Harvesting byType - Percentage Breakdown of Value Sales for Manual andAutomated for the Years 2012, 2020 & 2027 III-20
Table 46: Canada Current & Future Analysis for Cell Harvestingby Application - Peripheral Blood, Bone Marrow, Umbilical Cord,Adipose Tissue and Other Applications - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027 III-21
Table 47: Canada Historic Review for Cell Harvesting byApplication - Peripheral Blood, Bone Marrow, Umbilical Cord,Adipose Tissue and Other Applications Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 III-22
Table 48: Canada 15-Year Perspective for Cell Harvesting byApplication - Percentage Breakdown of Value Sales forPeripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissueand Other Applications for the Years 2012, 2020 & 2027 III-23
Table 49: Canada Current & Future Analysis for Cell Harvestingby End-Use - Biotech & Biopharma Companies, Research Institutesand Other End-Uses - Independent Analysis of Annual Sales inUS$ Thousand for the Years 2020 through 2027 III-24
Table 50: Canada Historic Review for Cell Harvesting by End-Use- Biotech & Biopharma Companies, Research Institutes and OtherEnd-Uses Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2012 through 2019 III-25
Table 51: Canada 15-Year Perspective for Cell Harvesting byEnd-Use - Percentage Breakdown of Value Sales for Biotech &Biopharma Companies, Research Institutes and Other End-Uses forthe Years 2012, 2020 & 2027 III-26
JAPAN III-27Increasing Demand for Regenerative Medicine in GeriatricHealthcare and Cancer Care to Drive Demand for Cell Harvesting III-27Exhibit 18: Japanese Population by Age Group (2015 & 2040):Percentage Share Breakdown of Population for 0-14, 15-64 and65 & Above Age Groups III-27Exhibit 19: Cancer Related Incidence and Deaths by Site inJapan: 2018 III-28Market Analytics III-29Table 52: Japan Current & Future Analysis for Cell Harvestingby Type - Manual and Automated - Independent Analysis of AnnualSales in US$ Thousand for the Years 2020 through 2027 III-29
Table 53: Japan Historic Review for Cell Harvesting by Type -Manual and Automated Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2012 through 2019 III-30
Table 54: Japan 15-Year Perspective for Cell Harvesting by Type- Percentage Breakdown of Value Sales for Manual and Automatedfor the Years 2012, 2020 & 2027 III-31
Table 55: Japan Current & Future Analysis for Cell Harvestingby Application - Peripheral Blood, Bone Marrow, Umbilical Cord,Adipose Tissue and Other Applications - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027 III-32
Table 56: Japan Historic Review for Cell Harvesting byApplication - Peripheral Blood, Bone Marrow, Umbilical Cord,Adipose Tissue and Other Applications Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 III-33
Table 57: Japan 15-Year Perspective for Cell Harvesting byApplication - Percentage Breakdown of Value Sales forPeripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissueand Other Applications for the Years 2012, 2020 & 2027 III-34
Table 58: Japan Current & Future Analysis for Cell Harvestingby End-Use - Biotech & Biopharma Companies, Research Institutesand Other End-Uses - Independent Analysis of Annual Sales inUS$ Thousand for the Years 2020 through 2027 III-35
Table 59: Japan Historic Review for Cell Harvesting by End-Use -Biotech & Biopharma Companies, Research Institutes and OtherEnd-Uses Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2012 through 2019 III-36
Table 60: Japan 15-Year Perspective for Cell Harvesting byEnd-Use - Percentage Breakdown of Value Sales for Biotech &Biopharma Companies, Research Institutes and Other End-Uses forthe Years 2012, 2020 & 2027 III-37
CHINA III-38Rising Incidence of Cancer Drives Cell Harvesting Market III-38Exhibit 20: Number of New Cancer Cases Diagnosed (in Thousands)in China: 2018 III-38Market Analytics III-39Table 61: China Current & Future Analysis for Cell Harvestingby Type - Manual and Automated - Independent Analysis of AnnualSales in US$ Thousand for the Years 2020 through 2027 III-39
Table 62: China Historic Review for Cell Harvesting by Type -Manual and Automated Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2012 through 2019 III-40
Table 63: China 15-Year Perspective for Cell Harvesting by Type -Percentage Breakdown of Value Sales for Manual and Automatedfor the Years 2012, 2020 & 2027 III-41
Table 64: China Current & Future Analysis for Cell Harvestingby Application - Peripheral Blood, Bone Marrow, Umbilical Cord,Adipose Tissue and Other Applications - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027 III-42
Table 65: China Historic Review for Cell Harvesting byApplication - Peripheral Blood, Bone Marrow, Umbilical Cord,Adipose Tissue and Other Applications Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 III-43
Table 66: China 15-Year Perspective for Cell Harvesting byApplication - Percentage Breakdown of Value Sales forPeripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissueand Other Applications for the Years 2012, 2020 & 2027 III-44
Table 67: China Current & Future Analysis for Cell Harvestingby End-Use - Biotech & Biopharma Companies, Research Institutesand Other End-Uses - Independent Analysis of Annual Sales inUS$ Thousand for the Years 2020 through 2027 III-45
Table 68: China Historic Review for Cell Harvesting by End-Use -Biotech & Biopharma Companies, Research Institutes and OtherEnd-Uses Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2012 through 2019 III-46
Table 69: China 15-Year Perspective for Cell Harvesting byEnd-Use - Percentage Breakdown of Value Sales for Biotech &Biopharma Companies, Research Institutes and Other End-Uses forthe Years 2012, 2020 & 2027 III-47
EUROPE III-48Cancer in Europe: Key Statistics III-48Exhibit 21: Cancer Incidence in Europe: Number of New CancerCases (in Thousands) by Site for 2018 III-48Ageing Population to Drive Demand for Cell Harvesting Market III-49Exhibit 22: European Population by Age Group (2016, 2030 &2050): Percentage Share Breakdown by Age Group for 0-14, 15-64, and 65 & Above III-49Market Analytics III-50Table 70: Europe Current & Future Analysis for Cell Harvestingby Geographic Region - France, Germany, Italy, UK and Rest ofEurope Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2020 through 2027 III-50
Table 71: Europe Historic Review for Cell Harvesting byGeographic Region - France, Germany, Italy, UK and Rest ofEurope Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2012 through 2019 III-51
Table 72: Europe 15-Year Perspective for Cell Harvesting byGeographic Region - Percentage Breakdown of Value Sales forFrance, Germany, Italy, UK and Rest of Europe Markets for Years2012, 2020 & 2027 III-52
Table 73: Europe Current & Future Analysis for Cell Harvestingby Type - Manual and Automated - Independent Analysis of AnnualSales in US$ Thousand for the Years 2020 through 2027 III-53
Table 74: Europe Historic Review for Cell Harvesting by Type -Manual and Automated Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2012 through 2019 III-54
Table 75: Europe 15-Year Perspective for Cell Harvesting byType - Percentage Breakdown of Value Sales for Manual andAutomated for the Years 2012, 2020 & 2027 III-55
Table 76: Europe Current & Future Analysis for Cell Harvestingby Application - Peripheral Blood, Bone Marrow, Umbilical Cord,Adipose Tissue and Other Applications - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027 III-56
Table 77: Europe Historic Review for Cell Harvesting byApplication - Peripheral Blood, Bone Marrow, Umbilical Cord,Adipose Tissue and Other Applications Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 III-57
Table 78: Europe 15-Year Perspective for Cell Harvesting byApplication - Percentage Breakdown of Value Sales forPeripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissueand Other Applications for the Years 2012, 2020 & 2027 III-58
Table 79: Europe Current & Future Analysis for Cell Harvestingby End-Use - Biotech & Biopharma Companies, Research Institutesand Other End-Uses - Independent Analysis of Annual Sales inUS$ Thousand for the Years 2020 through 2027 III-59
Table 80: Europe Historic Review for Cell Harvesting by End-Use -Biotech & Biopharma Companies, Research Institutes and OtherEnd-Uses Markets - Independent Analysis of Annual Sales in US$Thousand for Years 2012 through 2019 III-60
Table 81: Europe 15-Year Perspective for Cell Harvesting byEnd-Use - Percentage Breakdown of Value Sales for Biotech &Biopharma Companies, Research Institutes and Other End-Uses forthe Years 2012, 2020 & 2027 III-61
FRANCE III-62Table 82: France Current & Future Analysis for Cell Harvestingby Type - Manual and Automated - Independent Analysis of AnnualSales in US$ Thousand for the Years 2020 through 2027 III-62
Table 83: France Historic Review for Cell Harvesting by Type -Manual and Automated Markets - Independent Analysis of AnnualSales in US$ Thousand for Years 2012 through 2019 III-63
Table 84: France 15-Year Perspective for Cell Harvesting byType - Percentage Breakdown of Value Sales for Manual andAutomated for the Years 2012, 2020 & 2027 III-64
Table 85: France Current & Future Analysis for Cell Harvestingby Application - Peripheral Blood, Bone Marrow, Umbilical Cord,Adipose Tissue and Other Applications - Independent Analysis ofAnnual Sales in US$ Thousand for the Years 2020 through 2027 III-65
Table 86: France Historic Review for Cell Harvesting byApplication - Peripheral Blood, Bone Marrow, Umbilical Cord,Adipose Tissue and Other Applications Markets - IndependentAnalysis of Annual Sales in US$ Thousand for Years 2012 through2019 III-66
Table 87: France 15-Year Perspective for Cell Harvesting byApplication - Percentage Breakdown of Value Sales forPeripheral Blood, Bone Marrow, Umbilical Cord, Adipose Tissueand Other Applications for the Years 2012, 2020 & 2027 III-67
Go here to read the rest:
Global Cell Harvesting Market to Reach US$381,4 Million by the Year 2027 - Salamanca Press
- Hope Biosciences Research Foundation Authorized to Begin Phase II Clinical Trial in Stem Cell Therapy for Juvenile Idiopathic Arthritis - Business... - December 22nd, 2024
- What Are Stem Cells? Biomedical Beat Blog National Institute of ... - November 29th, 2024
- TVHS opens stem cell processing lab to expand biotherapies | VA Tennessee Valley health care | Veterans Affairs - Veterans Affairs - November 8th, 2024
- Understanding Mature Tissue or Organ Stem Cells and Their Clinical ... - November 8th, 2024
- Biology of stem cells: an overview - PMC - PubMed Central (PMC) - October 30th, 2024
- New government tech deals boost the business of cancer detection - GOV.UK - October 11th, 2024
- Stem cell therapy reverses type 1 diabetes in world first - Yahoo News UK - October 11th, 2024
- Advances in different adult stem cell-derived exosomal non-coding RNAs for the treatment of neurological disorders: a narrative review - Frontiers - September 26th, 2024
- Breakthrough technique may help speed understanding, treatment of MD, ALS - Harvard Gazette - September 14th, 2024
- Rostock University Explores Use of Stem Cells for Meat Cultivation with Help from Innocent Meat - vegconomist - the vegan business magazine - August 12th, 2024
- Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - July 31st, 2024
- Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 - July 31st, 2024
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update - July 31st, 2024
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 - July 31st, 2024
- Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024 - July 31st, 2024
- Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 - July 31st, 2024
- Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency... - July 31st, 2024
- Targeting the stem cell niche micro-environment as therapeutic strategies in aging - Frontiers - June 28th, 2024
- International trial introduces another curative option for sickle cell disease - EurekAlert - June 28th, 2024
- HOX genes in stem cells: Maintaining cellular identity and regulation of differentiation - Frontiers - June 28th, 2024
- Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and... - June 21st, 2024
- Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management - June 21st, 2024
- Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC. - June 21st, 2024
- Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Samer Kaba, MD as Chief Medical Officer - June 21st, 2024
- API and the University of Alberta Break Ground in Edmonton on Canada’s Largest Manufacturing Facility for Critical Medicines - June 21st, 2024
- Syntekabio Signs Memorandum of Understanding with bioSeedin/ACROBiosystems - June 21st, 2024
- Rapafusyn Pharmaceuticals Secures $28 Million Series A to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform - June 21st, 2024
- Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog... - June 21st, 2024
- Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting - June 21st, 2024
- Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing - June 21st, 2024
- NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - June 21st, 2024
- Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran - June 21st, 2024
- Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’... - June 21st, 2024
- Radiopharm Receives Strategic Investment for up to A$18 million - June 21st, 2024
- Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee - June 21st, 2024
- Trading by management and close relations of management - June 21st, 2024
- Major shareholder announcement - June 21st, 2024
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - June 21st, 2024
- Nature retracts highly cited 2002 paper that claimed adult stem cells could become any type of cell - Retraction Watch - June 19th, 2024
- Shares of Biotech MicroCap Rip on Licensing Talks - The Globe and Mail - June 15th, 2024
- Syntekabio to Showcase Advanced AI Drug Discovery Technologies at BIO International Convention 2024 - May 23rd, 2024
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 23rd, 2024
- Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist... - May 23rd, 2024
- Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus... - May 23rd, 2024
- Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 - May 23rd, 2024
- New York Blood Center Enterprises Celebrates the Expansion of Cell & Gene Therapy GMP Manufacturing Capabilities at the Grand Opening of... - May 23rd, 2024
- Syneos Health Leaders Recognized as PM360 ELITE 100 Award Recipients - May 23rd, 2024
- Kane Biotech Announces First Quarter 2024 Financial Results - May 23rd, 2024
- Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast - May 23rd, 2024
- Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy - May 23rd, 2024
- Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024 - May 23rd, 2024
- 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results - May 23rd, 2024
- Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting - May 23rd, 2024
- Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024 - May 23rd, 2024
- Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences - May 23rd, 2024
- NANOBIOTIX to Present at the Jefferies Global Healthcare Conference - May 23rd, 2024
- Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - May 23rd, 2024
- Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual... - May 23rd, 2024
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
- NOT-AR-23-022: Request for Information on Themes for the NIAMS ... - National Institutes of Health (.gov) - December 3rd, 2023
- December 2023: Intramural Papers of the Month - Environmental Factor Newsletter - December 1st, 2023
- CNA Explains: What is cord blood banking and why do parents do it? - CNA - December 1st, 2023
- Regulation of myogenesis and adipogenesis by the electromagnetic ... - Nature.com - December 1st, 2023
- The effects of vitamin K on bone health - News-Medical.Net - December 1st, 2023
Recent Comments